ZONEGRAN

ZONEGRAN is prescribed as an adjunctive therapy for treating partial seizures in adults with epilepsy. ZONEGRAN (zonisamide) is recommended as an adjunctive therapy for managing partial seizures in adults. However, its safety and efficacy in pediatric patients below the age of 16 have not been established.

Zonisamide is utilized in combination with other medications to address specific types of seizures. It belongs to a class of drugs known as anticonvulsants and operates by reducing abnormal electrical activity in the brain.

On April 25, 2022, Glenmark issued a recall of certain lots of zonisamide capsules at the consumer level. This action was taken due to issues related to gaps in the microbiology quality control system or a lack of stability data.

Zonisamide serves as an anticonvulsant primarily used for the treatment of seizure disorders, including epilepsy. Anticonvulsant medications modulate the actions of neurotransmitters, resulting in reduced excitability of brain cells (neurons). In cases of bipolar disorder, zonisamide is primarily used to address depression.

Common side effects may include loss of appetite, memory impairment, drowsiness, impaired concentration, altered walking, impaired coordination, and feelings of anger.

In cases of overdose or intolerance to the drug, patients may experience vision loss. Other potential side effects include allergies, fever, and difficulties in speaking or thinking. However, hair loss is not associated with the use of Zonisamide, so individuals taking it should not experience hair loss.

The use of zonisamide has been frequently linked to adverse events related to the central nervous system. Zonisamide may lead to issues with concentration, attention, memory, thinking, speech, or language.

Are Gabapentin and Zonegran the Same Thing? Zonegran (zonisamide) and gabapentin are both anticonvulsants used for the management of seizures in individuals with epilepsy. Gabapentin is also utilized to alleviate nerve pain caused by shingles (herpes zoster). Notable brand names for gabapentin include Neurontin, Gralise, Neuraptine, and SmartRx Gaba-V Kit.

There were no significant differences observed between the two groups in terms of the average reduction in pain intensity. The gabapentin group showed a reduction of 59.73%, while the topiramate group had a reduction of 55% (p=0.48).

Zonisamide is one of the medications commonly used to treat epilepsy. Some of these medications are also effective in addressing neuropathic pain.

Using gabapentin in combination with zonisamide may heighten side effects such as dizziness, drowsiness, confusion, and difficulty concentrating. Some individuals, particularly the elderly, may also experience impaired thinking, judgment, and motor coordination.

The recommended therapeutic range for seizure control typically falls between 10-40 ?g/mL. Concentrations exceeding 80 ?g/mL may contribute to adverse effects. Pharmacokinetics can vary widely, especially when other medications are involved or if there is compromised renal function.

Kidney stones occurred in approximately 1 in 80 individuals, typically after 6 to 12 months of Zonegran use. Most individuals who developed kidney stones had a history of previous occurrences. If you experience symptoms suggestive of a kidney stone, such as sudden back pain, abdominal pain, or blood in the urine, it is crucial to contact your doctor immediately.

Among the currently available antiseizure medications, lamotrigine (Lamictal; GlaxoSmithKline) is known for its effectiveness in controlling various types of seizures while being considered the least sedative for patients.

FDA Licensed treatments for seizures include levetiracetam (Keppra, Spritam), phenytoin (Dilantin) , zonisamide (Zonegran), carbamazepine (Tegretol), oxcarbazepine (Trileptal), valproic acid derivatives, topiramate (Topamax) and phenobarbital. Phenobarbital is a barbiturate that can treat focal onset and generalized seizures.

Zonegran (zonisamide) and Keppra (levetiracetam) are anticonvulsants used for the management of seizures in individuals with epilepsy. They share common side effects such as drowsiness, dizziness, fatigue, and loss of appetite.

Are Topamax and Zonegran the Same Thing? Topamax (topiramate) and Zonegran (zonisamide) are anticonvulsants utilized to prevent epileptic seizures. Topamax is also used for migraine prevention.

Both drugs are effective for their licensed indications. Your doctor will discuss which medication is the most suitable considering your health circumstances and condition which is being treated.

In a study, 57% of patients in the zonisamide group experienced a loss of at least 5% of their initial body weight, compared to only 10% in the placebo group. Additionally, 23% of those in the zonisamide group lost at least 10% of their initial body weight compared to none in the placebo group (P=).

Studies have shown that individuals taking Topamax typically lose an average of slightly over 11 lbs (approximately 5 kg) compared to those taking a placebo (a ‘sugar pill’). Topamax has also demonstrated an improvement in insulin sensitivity, particularly in individuals taking antipsychotic medications like olanzapine (Zyprexa).

Topamax is a brand-name prescription medication that is FDA-approved for specific purposes, including preventing migraine headaches in adults and children aged 12 years and older, as well as treating epilepsy in adults and children aged 2 years and older, specifically for partial-onset seizures.

Dizziness, somnolence, loss of appetite, ataxia, fatigue, abnormal thinking, and confusion are common side effects associated with the use of zonisamide. Zonisamide may also lead to mild to moderate weight loss.

Are Topamax and Neurontin the Same Thing? Topamax (topiramate) and Neurontin (gabapentin) are both anticonvulsants used to manage and prevent epileptic seizures. Topamax is also used for preventing migraine headaches, while Neurontin is utilized for treating nerve pain caused by shingles (herpes zoster).

Valproic acid (Depakote): This is a standard broad-spectrum antiepileptic drug (AED) that is effective against various types of seizures, making it the preferred choice for generalized seizure types.

Zonisamide, similar to topiramate, is a carbonic anhydrase inhibitor. However, reports from patients with seizures suggest that it has a lower incidence of paresthesias (2.5%11.5% vs. ?22% for topiramate) and metabolic acidosis.

For individuals struggling to lose weight, medications can be of assistance. Some popular examples of weight loss pills include Contrave (naltrexone/bupropion), Qsymia (phentermine/topiramate ER), and phentermine (Adipex-P).

Potential side effects of Qulipta may encompass nausea, weight loss, and increased liver enzyme levels. Additionally, some individuals may experience allergic reactions.

In conclusion, our findings indicate that zonisamide is equally effective as topiramate in migraine prophylaxis and can be considered an alternative treatment option, especially in cases where topiramate is not well-tolerated.

Zonisamide falls under the category of medications known as anticonvulsants. It operates by reducing abnormal electrical activity in the brain.

Zonegran has the effect of increasing monoamines, which can suppress NPY and AgRP neurons in the hypothalamus, subsequently reducing appetite. It may also stimulate pro-opiomelanocortin receptors in the hypothalamus, further suppressing appetite. Most patients do not experience side effects.

In a study, 57% of patients in the zonisamide group lost at least 5% of their initial body weight, whereas only 10% of those in the placebo group achieved the same result. Additionally, 23% of patients in the zonisamide group lost at least 10% of their initial body weight, while none in the placebo group did (P=).

Long-term assessment revealed that zonisamide was associated with a significantly slower rate of BMI and weight increase compared to placebo (P = . 01). None of the individuals in the zonisamide group experienced significant weight gain, whereas 33% of placebo-treated patients did (P = . 009).

In this initial trial of short duration, with an open-label approach, the combined administration of zonisamide and bupropion led to greater weight loss compared to the use of zonisamide alone. Out of the participants, six individuals in the combination group and two in the zonisamide group achieved a weight loss of at least 5% of their body weight.

Despite the various side effects, it’s important to note that hair loss is not among them when taking Zonisamide. Therefore, individuals using Zonisamide should not experience hair loss.

Topiramate, when used for weight loss, is an anticonvulsant medication known for its efficacy in managing epilepsy, both generalized or focal seizures, and migraine prevention. Additionally, it has been shown to result in weight loss.

Zonisamide (Zonegran) can potentially impair your concentration, memory, speech, coordination, mood (including new or worsening depression), and cause drowsiness. Individuals should exercise caution when engaging in activities such as driving that require mental alertness while taking zonisamide.

This medication may induce agitation, irritability, or other abnormal behaviors in some individuals. It could also lead to suicidal thoughts or tendencies, as well as increased depression. If you or your caregiver notice any of these side effects, it’s crucial to inform your doctor immediately.

Zonisamide does not induce its own metabolism and does not affect liver enzymes.

Discontinuation of zonisamide due to psychiatric and cognitive adverse events.